跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
WEZENLA 130 MG CONCENTRADO PARA SOLUCION PARA PERFUSION - CIMA-AEMPS Drug Approval Details
Approvals
/
CIMA-AEMPS
/
WEZENLA 130 MG CONCENTRADO PARA SOLUCION PARA PERFUSION
Approved
STANDARD
WEZENLA 130 MG CONCENTRADO PARA SOLUCION PARA PERFUSION
Amgen Technology (Ireland) Unlimited Company
🇪🇸 Spanish Agency of Medicines and Medical Devices
Approval Date
Jun 26, 2024
Approval ID
a897e18ff8217b78
Company
Amgen Technology (Ireland) Unlimited Company
Type
Standard
Approval Details
Approval Id
a897e18ff8217b78
Drug Cima Aemps Name
WEZENLA 130 MG CONCENTRADO PARA SOLUCION PARA PERFUSION
Register Number
1241823004
Holder Company Name
Amgen Technology (Ireland) Unlimited Company
Marketing Company Name
Amgen S.A.
Holder Company Detail Path
/organization/amgen-technology-ireland-unlimited-company
Marketing Company Detail Path
/organization/amgen-sa
Authorization Date
2024-06-26
Dosage Form
CONCENTRADO PARA SOLUCIÓN PARA PERFUSIÓN
Dose
130 mg
Route Of Administration
VÍA INTRAVENOSA
Prescription Type
Uso Hospitalario
Commercialized
Yes
Company Name
Amgen Technology (Ireland) Unlimited Company
Company Detail Path
/organization/amgen-technology-ireland-unlimited-company
Company Information
Pharmaceutical Company Name
AMGEN TECHNOLOGY (IRELAND) UNLIMITED COMPANY
Country Name
Ireland
City Name
dun laoghaire,country_ie
Address
Pottery Road
Active Ingredients
USTEKINUMAB
90 mg
Approved
Quick Info
Agency
CIMA-AEMPS
Country
🇪🇸
Approval Date
Jun 26, 2024
Approval ID
a897e18ff8217b78
Type
Standard
Back to CIMA-AEMPS Approvals